Latest Radiopharm Theranostics (ASX:RAD) News

Radiopharm Theranostics reports promising second interim Phase 2b results for RAD 101, showing 90% concordance with MRI in detecting brain metastases and encouraging sensitivity and specificity trends.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Radiopharm Theranostics reported a 44% increase in net loss to $27 million for the half-year ended December 2025, driven by expanded R&D spending. The company bolstered its cash reserves through a $35 million placement while progressing multiple clinical trials across its radiopharmaceutical pipeline.

Radiopharm Theranostics has initiated dosing in its Phase 1/2a clinical trial of BetaBart, a novel radiotherapeutic developed with MD Anderson Cancer Center, targeting aggressive solid tumors.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

Radiopharm Theranostics has secured ethics approval to begin a Phase 1 clinical trial of RAD 402, a pioneering radiotherapeutic targeting advanced prostate cancer using terbium-161. This marks a significant step in developing a potentially safer, more effective treatment option.

Radiopharm Theranostics has reached the halfway mark in enrolling patients for its Phase 2b trial of RAD101, a novel imaging agent targeting brain metastases. Early data suggest RAD101 may outperform MRI in distinguishing tumor recurrence from radiation damage.

Radiopharm Theranostics has successfully enrolled the second cohort in its Phase 1 trial of 177Lu-RAD204, with the Data Safety Monitoring Committee greenlighting a dose increase to 90mCi for the third cohort. Early results show promising tumor targeting and safety in multiple advanced cancers.

Radiopharm Theranostics has secured FDA approval to initiate a Phase I trial targeting B7H3 and raised A$40 million to accelerate its radiopharmaceutical programs. The company also appointed renowned oncologist Dr Oliver Sartor to its Scientific Advisory Board.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.